Literature DB >> 20392294

Leptin in sepsis: a well-suited biomarker in critically ill patients?

Rodolfo Leonel Bracho-Riquelme1, Miguel Arturo Reyes-Romero.   

Abstract

The value of monitoring serum leptin in critically ill patients is important for early diagnosis and differentiation between sepsis and non-infectious systemic inflammatory response syndrome (SIRS). The early diagnosis of sepsis, the identification of its origin, and an adequate therapeutic management are crucial to overcome sepsis-associated mortality. Cytokine levels are an obvious choice as sepsis markers, since cytokines are key mediators of the inflammatory response to sepsis. Leptin, a hormone mainly generated by adipocytes, acts centrally in the hypothalamus to regulate body weight and energy expenditure. There is, however, strong evidence that leptin is also involved in cell-mediated immunity and cytokine crosstalk. The finding that a serum leptin threshold of 38 microg/l can distinguish between sepsis and non-infectious SIRS (sensitivity 91.2%, specificity 85%) is the major finding in the article by Yousef and colleagues (in this issue). Much remains to be learned about the precise mechanisms by which leptin signaling participates in sepsis and non-infectious SIRS. This knowledge will potentially contribute to new therapeutic approaches.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20392294      PMCID: PMC2887146          DOI: 10.1186/cc8917

Source DB:  PubMed          Journal:  Crit Care        ISSN: 1364-8535            Impact factor:   9.097


Yousef and colleagues' article discussing the value of monitoring serum leptin in critically ill patients touches on the important matter of early diagnosis and differentiation between sepsis and non-infectious systemic inflammatory response syndrome (SIRS) [1]. The early diagnosis of sepsis, the identification of its origin, and an adequate therapeutic management are crucial to overcome sepsis-associated mortality [2]. Cytokine levels are the obvious choice as sepsis markers since cytokines are key mediators of the inflammatory response to sepsis. Among the cytokines, TNFα, IL-1, IL-6, IFNγ, IL-10, and IL-13 best characterize the immune dysregulation during sepsis [3]. In 1998 Bornstein and colleagues reported an increase in leptin levels and the loss of the diurnal rhythm of this adipokine in survivors of acute sepsis [4]. They also observed that low leptin and high IL-6 levels indicated an unfavorable prognosis in patients with sepsis syndrome. Owing to contradictory findings in latter reports [5-9], however, the interest in leptin as a sepsis marker waned. Leptin, a hormone mainly generated by adipocytes, acts centrally in the hypothalamus to regulate body weight and energy expenditure. There is, however, strong evidence that leptin is also involved in cell-mediated immunity and cytokine crosstalk [10]. Yousef and colleagues confirmed a positive correlation between leptin and IL-6 and TNFα in patients with sepsis [11]. The finding that a serum leptin threshold of 38 μg/l can distinguish between sepsis and non-infectious SIRS (sensitivity 91.2%, specificity 85%) is the major finding in the article by Yousef and colleagues (in this issue). The matter at heart in the early differentiation between sepsis and non-infectious SIRS is the impact on outcome. In patients with surgically confirmed secondary peritonitis, our group found that a serum level of leptin <10 ng/ml was accompanied by a 4.25-fold increase in the risk of death. Our results were limited to moderate to severe peritonitis where the measurement was made 24 hours into the postoperative period (± 2 hours) [12]. Since leptin apparently inhibits an excessive or harmful lipopolysaccharide-induced inflammatory reaction to or prevents TNFα-induced lethality in sepsis [13], it would have been interesting if Yousef and colleagues had reported the results of the 11 patients that died in their study group [1]. Our findings [12] concur with those reported by Bornstein and colleagues: an increase is found in leptin serum levels in septic patients, while a low leptin level is associated with a negative outcome [4] - possibly due to the lack of the protective effect of leptin [13]. Yousef and colleagues' report contributes to our understanding of the regulation of the inflammatory cascade in sepsis [1]. Much remains to be learned about the precise mechanisms by which leptin signaling participates in sepsis and non-infectious SIRS. This knowledge will potentially contribute to new therapeutic approaches.

Abbreviations

IFN: interferon; IL: interleukin; SIRS: systemic inflammatory response syndrome; TNF: tumor necrosis factor.

Competing interests

The authors declare that they have no competing interests.
  12 in total

1.  Leptin and interleukin-6 in sepsis.

Authors:  D J Torpy; S R Bornstein; G P Chrousos
Journal:  Horm Metab Res       Date:  1998-12       Impact factor: 2.936

2.  Serum leptin levels in septic men correlate well with C-reactive protein (CRP) and TNF-alpha but not with BMI.

Authors:  P Maruna; R Gürlich; R Frasko; M Haluzík
Journal:  Physiol Res       Date:  2001       Impact factor: 1.881

3.  Serum leptin levels are higher but are not independently associated with severity or mortality in the multiple organ dysfunction/systemic inflammatory response syndrome: a matched case control and a longitudinal study.

Authors:  E D Papathanassoglou; J A Moynihan; M H Ackerman; C S Mantzoros
Journal:  Clin Endocrinol (Oxf)       Date:  2001-02       Impact factor: 3.478

4.  Serum leptin concentrations and their relation to metabolic abnormalities in human sepsis.

Authors:  G L Carlson; M Saeed; R A Little; M H Irving
Journal:  Am J Physiol       Date:  1999-04

5.  Plasma leptin levels are increased in survivors of acute sepsis: associated loss of diurnal rhythm, in cortisol and leptin secretion.

Authors:  S R Bornstein; J Licinio; R Tauchnitz; L Engelmann; A B Negrão; P Gold; G P Chrousos
Journal:  J Clin Endocrinol Metab       Date:  1998-01       Impact factor: 5.958

6.  The diagnostic value of serum leptin monitoring and its correlation with tumor necrosis factor-alpha in critically ill patients: a prospective observational study.

Authors:  Ayman Abd Al-Maksoud Yousef; Yasser Mohamed Amr; Ghada Abdulmomen Suliman
Journal:  Crit Care       Date:  2010-03-15       Impact factor: 9.097

7.  Leptin deficiency enhances sensitivity to endotoxin-induced lethality.

Authors:  R Faggioni; G Fantuzzi; C Gabay; A Moser; C A Dinarello; K R Feingold; C Grunfeld
Journal:  Am J Physiol       Date:  1999-01

8.  [Meningococcal sepsis in pediatrics. Parameters associated with poor outcome].

Authors:  A Blanco Quirós; J Casado Flores; M Nieto Moro; J A Garrote Adrados; E Arranz Sanz; J Asensio Antón
Journal:  An Pediatr (Barc)       Date:  2004-10       Impact factor: 1.500

9.  A leptin serum concentration less than 10 ng/ml is a predictive marker of outcome in patients with moderate to severe secondary peritonitis.

Authors:  R L Bracho-Riquelme; M A Reyes-Romero; N Pescador; A I Flores-García
Journal:  Eur Surg Res       Date:  2008-06-05       Impact factor: 1.745

10.  Relationship of plasma leptin to plasma cytokines and human survivalin sepsis and septic shock.

Authors:  F Arnalich; J López; R Codoceo; M Jim nez; R Madero; C Montiel
Journal:  J Infect Dis       Date:  1999-09       Impact factor: 5.226

View more
  3 in total

1.  Evaluation of leptin, interleukin-1 beta and tumor necrosis factor alpha in serum of malaria patients as prognostic markers of treatment outcome.

Authors:  Mariam Abdulrhman Al-Fadhli; Mohammad Ahmed Saraya; Jafar Abdulrida Qasem
Journal:  Asian Pac J Trop Biomed       Date:  2014-06

Review 2.  Endocrine dysfunction in sepsis: a beneficial or deleterious host response?

Authors:  Valeriu Gheorghiţă; Alina Elena Barbu; Monica Livia Gheorghiu; Florin Alexandru Căruntu
Journal:  Germs       Date:  2015-03-02

3.  Diagnostic value of serum leptin and a promising novel diagnostic model for sepsis.

Authors:  Mingyi Chen; Bin Wang; Yaping Xu; Zihui Deng; Hui Xue; Luhuan Wang; Lei He
Journal:  Exp Ther Med       Date:  2014-01-27       Impact factor: 2.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.